{"id":33455,"date":"2020-08-13T11:04:13","date_gmt":"2020-08-13T10:04:13","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33455"},"modified":"2021-03-18T11:23:51","modified_gmt":"2021-03-18T11:23:51","slug":"biosimilars-biologics-2019-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/","title":{"rendered":"Biosimilars &#038; Biologics 2019 Speakers"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>\n\tOur <br>Speakers (A-Z)<br>\n\t<\/h2>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/barbara-valenta-singer\/\" title=\"Barbara Valenta-Singer\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33514&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/barbara-valenta-singer\/barbara_valenta-singer_fresenius_kabi_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Barbara_Valenta-Singer_Fresenius_Kabi_Biotech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/barbara-valenta-singer\/\" title=\"Barbara Valenta-Singer\">\n\t\t\t\t\t\t\tBarbara Valenta-Singer\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Chief Medical Officer Fresenius-Kabi SwissBioSim<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/barbara-valenta-singer\/\" title=\"Biosimilar global development: after >10years are we closer ?&#8221; target=&#8221;_self&#8221; rel=&#8221;noopener noreferrer&#8221;>\n\tBiosimilar global development: after &gt;10years are we closer ?\n\t\t\t<\/a>\n\t<\/h3>\n\t<p><strong>Member of the Austrian Drug Evaluation Committee (sick&nbsp; funds\/reimbursement)<\/strong><\/p>\n<ul>\n<li>Board of Austrian Pharmacological Society (APHAR)<\/li>\n<li>Task force Rare Disease Europa Bio and EBE<\/li>\n<li>Working Party Advanced Therapies<\/li>\n<li>July 2010 -2013: permanent industry representative EUCERD (EU Commission<\/li>\n<li>Working party for Rare Diseases<\/li>\n<\/ul>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/\" title=\"Cate Lockhart\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33503&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/lockhart_cate_biologics_biosimilars_collective_intelligence_consortium_bbcic_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;10&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;NIKON D7000&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;1445341857&quot;,&quot;copyright&quot;:&quot;University of Washington&quot;,&quot;focal_length&quot;:&quot;80&quot;,&quot;iso&quot;:&quot;100&quot;,&quot;shutter_speed&quot;:&quot;0.005&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/\" title=\"Cate Lockhart\">\n\t\t\t\t\t\t\tCate Lockhart\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Program Director at Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org)<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/\" title=\"The state of US biosimilar utilization and post-marketing surveillance initiatives to support treatment and coverage decisions\" target=\"_self\" rel=\"noopener noreferrer\">\n\tThe state of US biosimilar utilization and post-marketing surveillance initiatives to support treatment and coverage decisions\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Cate Lockhart, MS, PharmD, PhD is the Program Director for the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org) where she is responsible for both the business and research programs of this large, multi-stakeholder research collaboration.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/\" title=\"Emile van Corven\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33461&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/emile_van_corven_biotech_pharma_summit_bioceros_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/\" title=\"Emile van Corven\">\n\t\t\t\t\t\t\tEmile van Corven\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Chief Development Officer at Bioceros<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/\" title=\"Solve the technical challenges in developing biosimilar antibodies\" target=\"_self\" rel=\"noopener noreferrer\">\n\tSolve the technical challenges in developing biosimilar antibodies\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry: global head of process development and pilot plant GMP manufacturing of MAbs and vaccines (Crucell\/J&amp;J), and the development or recombinant proteins (Pharming).<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/plugins\/beaver-builder-lite-version\/img\/pixel.png\" alt=\"\" itemprop=\"image\" onerror=\"this.style.display='none'\">\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/fernanda-aleixo\/\" title=\"Fernanda Aleixo\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33467&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/fernanda-aleixo\/fernanda_aleixo_mylan_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;9&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;NIKON D300&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;1551005148&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;65&quot;,&quot;iso&quot;:&quot;250&quot;,&quot;shutter_speed&quot;:&quot;0.00625&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fernanda_Aleixo_Mylan_BioTech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/fernanda-aleixo\/\" title=\"Fernanda Aleixo\">\n\t\t\t\t\t\t\tFernanda Aleixo\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Director, Policy &amp; Market Access at Mylan<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/fernanda-aleixo\/\" title=\"Portugal, a case of success of pioneer measures that can inspire other countries\" target=\"_self\" rel=\"noopener noreferrer\">\n\tPortugal, a case of success of pioneer measures that can inspire other countries\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Fernanda Aleixo is specialist in Regulatory Affairs and member of the council of specialists of the National Association of Pharmacists.<\/p>\n<p>Developed several activities with different stakeholders aiming to increase the education of the science behind the biosimilars medicines with the goal to share their value for the society, to increase the confidence on these health technologies, and to contribute for more rational and conscientious decisions.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/francois-xavier-frapaise\/\" title=\"Francois-Xavier Frapaise\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33548&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/francois-xavier-frapaise\/francois-xavier_frapaise_biotech_pharma_summit_profile_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Francois-Xavier_Frapaise_Biotech_Pharma_Summit_profile_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/francois-xavier-frapaise\/\" title=\"Francois-Xavier Frapaise\">\n\t\t\t\t\t\t\tFrancois-Xavier Frapaise\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Principal at F.-X. Frapaise Consulting<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/francois-xavier-frapaise\/\" title=\"Biosimilars: patient perspectives, challenges and emerging solutions\" target=\"_self\" rel=\"noopener noreferrer\">\n\tBiosimilars: patient perspectives, challenges and emerging solutions\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Dr. Francois-Xavier Frapaise, M.D has over 35 years of international drug development, strategic planning and marketing experience at major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck&nbsp;&nbsp;and Abbott; he has hold multiple C-level positions (CSO,CMO,CEO) in different Pharmacos in the US and Europe.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/gillian-woollett\/\" title=\"Gillian Woollett\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33473&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/gillian-woollett\/gillian_woollett_avalere_health_biotech_pharma_summit_profile_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;3.5&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;NIKON D4S&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;1516838400&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;135&quot;,&quot;iso&quot;:&quot;1600&quot;,&quot;shutter_speed&quot;:&quot;0.01&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Gillian_Woollett_Avalere_Health_BioTech_Pharma_Summit_Profile_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/gillian-woollett\/\" title=\"Gillian Woollett\">\n\t\t\t\t\t\t\tGillian Woollett\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Senior Vice President at Avalere Health<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/gillian-woollett\/\" title=\"International harmonization and regulatory convergence\" target=\"_self\" rel=\"noopener noreferrer\">\n\tInternational harmonization and regulatory convergence\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Gillian Woollett, Senior Vice President, leads our FDA Practice. She provides the \u201cprequel\u201d of scientific and regulatory strategic policy expertise that supports medicinal products gaining approval at the FDA in a manner that allows them to be successful in the public and private reimbursement world. She is building a bridge for Avalere clients from the FDA space into the traditionally separate Centers for Medicare &amp; Medicaid Services and healthcare policy\/business world.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/joao-goncalves\/\" title=\"Joa\u0303o Gonc\u0327alves\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2.jpeg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2-201&#215;300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2-686&#215;1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2-768&#215;1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2-630&#215;940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2-420&#215;627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2-315&#215;470.jpeg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33491&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/joao-goncalves\/joao_goncalves_fful_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2.jpeg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2-201&#215;300.jpeg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Joao_Goncalves_FFUL_BioTech_Pharma_Summit_2-686&#215;1024.jpeg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/joao-goncalves\/\" title=\"Joa\u0303o Gonc\u0327alves\">\n\t\t\t\t\t\t\tJoa\u0303o Gonc\u0327alves\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Group Leader\/Principal Investigator at iMed-The Research Institute for Medicines<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/joao-goncalves\/\" title=\"Immunogenicity: anticipating and avoiding issues for biosimilar development\" target=\"_self\" rel=\"noopener noreferrer\">\n\tImmunogenicity: anticipating and avoiding issues for biosimilar development\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Joa\u0303o Gonc\u0327alves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Instituto de Medicina Molecular and Professor of Immunology and Biotechnology both part of the Faculty of Pharmacy, University of Lisbon, Portugal. He is also Head of Antibody Engineering Laboratory at iMed \u2013 Faculdade Farmacia Universidade Lisboa.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/jose-marona\/\" title=\"Jos\u00e9 Marona\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33535&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/jose-marona\/jose_marona_egas_moniz_reumatologia_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jose_Marona_Egas_moniz_Reumatologia_BioTech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/jose-marona\/\" title=\"Jos\u00e9 Marona\">\n\t\t\t\t\t\t\tJos\u00e9 Marona\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Resident of Rheumatology at Centro Hospitalar de Lisboa Ocidental, EPE<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/jose-marona\/\" title=\"Switching to biosimilars: What have we learned?\" target=\"_self\" rel=\"noopener noreferrer\">\n\tSwitching to biosimilars: What have we learned?\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Dr. Jos\u00e9 Marona initiated Rheumatology residentship in 2016 at Hospital Egas Moniz \u2013 CHLO (Lisbon, Portugal). Since 2017 he is also a volunteer lecturer of Rheumatology in NOVA Medical School (Lisbon, Portugal) and a collaborator at the Center of Chronic Diseases from NOVA Medical School (CEDOC-NMS). He has participated in several clinical trials and research projects with particular focus on the impact of Biosimilars in the Portuguese market.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/justin-stebbing\/\" title=\"Justin Stebbing\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33497&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/justin-stebbing\/justin_stebbing_biotech_pharma_summit_imperial_college_london_profile_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Justin_Stebbing_BioTech_Pharma_Summit_Imperial_College_London_Profile_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/justin-stebbing\/\" title=\"Justin Stebbing\">\n\t\t\t\t\t\t\tJustin Stebbing\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Professor of Cancer Medicine and Oncology at Imperial College London<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/justin-stebbing\/\" title=\"Clinical Evidence of Trastuzumab Biosimilar\" target=\"_self\" rel=\"noopener noreferrer\">\n\tClinical Evidence of Trastuzumab Biosimilar\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Professor Justin Stebbing at Imperial specialises in a range of malignancies, their treatment with biologics (breast, GI and lung and clinical trials), having originally trained in medicine at Trinity College Oxford, where he gained a first class degree. After completion of junior doctor posts in Oxford, he undertook training and a residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew\u2019s Hospitals.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/lorraine-fincham\/\" title=\"Lorraine Fincham\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33520&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/lorraine-fincham\/lorraine_fincham_nhs_nihr_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;2.2&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;iPhone 6s&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;1461064522&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;4.15&quot;,&quot;iso&quot;:&quot;80&quot;,&quot;shutter_speed&quot;:&quot;0.03030303030303&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorraine_Fincham_NHS_NIHR_BioTech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/lorraine-fincham\/\" title=\"Lorraine Fincham\">\n\t\t\t\t\t\t\tLorraine Fincham\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Commercial Research Initiative Manager at NIHR Clinical Research Network Coordinating Centre<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/lorraine-fincham\/\" title=\"Enabling an NHS research-ready workforce to embrace the biosimilars boom\" target=\"_self\" rel=\"noopener noreferrer\">\n\tEnabling an NHS research-ready workforce to embrace the biosimilars boom\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Lorraine&nbsp;Fincham is the Commercial Research Initiative Manager for the NIHR Clinical Research Network (CRN). Lorraine has worked actively as an academic researcher for several London Universities, working on prostate and bowel cancer studies after finishing her degree in Psychology and MSc in Health Psychology. She moved to the NIHR Clinical Research Network in 2007, firstly working locally in the North West London Diabetes Research Network as a Primary Care specialist before moving to the NIHR CRN Coordinating Centre in 2010.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/ned-pojskic\/\" title=\"Ned Pojskic\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33508&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/ned-pojskic\/nedzad_pojskic_green_shield_canada_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;3.5&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;Canon EOS DIGITAL REBEL XS&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;1375209417&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;18&quot;,&quot;iso&quot;:&quot;200&quot;,&quot;shutter_speed&quot;:&quot;0.033333333333333&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nedzad_Pojskic_Green_Shield_Canada_BioTech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/ned-pojskic\/\" title=\"Ned Pojskic\">\n\t\t\t\t\t\t\tNed Pojskic\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Leader, Pharmacy &amp; Health Provider Relations at Green Shield Canada (GSC)<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/ned-pojskic\/\" title=\"Biosimilar Transition \u2013 A Canadian Insurer\u2019s Experience and Perspective\" target=\"_self\" rel=\"noopener noreferrer\">\n\tBiosimilar Transition \u2013 A Canadian Insurer\u2019s Experience and Perspective\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Ned Pojskic is Green Shield Canada\u2019s Leader for Pharmacy and Health Provider Relations. In this role, he is responsible for setting GSC\u2019s strategic direction with respect to provider and drug benefits management. He takes the lead in managing stakeholder relations with all health care providers, including pharmacy, dental, and paramedical. Ned is also responsible for overall drug formulary management, including pricing and policy as well as pharmaceutical industry partnerships.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/nikolai-brun\/\" title=\"Nikolai Brun\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33485&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/nikolai-brun\/nikolai_brun_dkma_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Nikolai_Brun_dkma_BioTech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Nikolai_Brun_dkma_BioTech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/nikolai-brun\/\" title=\"Nikolai Brun\">\n\t\t\t\t\t\t\tNikolai Brun\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Chief Medical Officer and Director of the Division for Medical Evaluation and Biostatistics at Danish Medicines Agency<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/nikolai-brun\/\" title=\"Danish experience with switching treatments for patients on to Biosimilar products \u2013 regulatory initiatives\" target=\"_self\" rel=\"noopener noreferrer\">\n\tDanish experience with switching treatments for patients on to Biosimilar products \u2013 regulatory initiatives\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Graduated from University of Copenhagen (Medical Doctor) in 1994 and obtained a PhD-degree from University of Copenhagen with extensive technical studies at University of Pennsylvania in 1998.<\/p>\n<p>Dr. Nikolai Brun practiced as a physician in the clinical field (Pediatrics) for a couple of years before continuing research and development work in the pharmaceutical industry especially working with biopharmaceuticals. Dr Brun has authored a long list of publications in high-impact journals.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/rahul-padhye\/\" title=\"Rahul Padhye\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33541&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/rahul-padhye\/rahul-padhye-rahul-padhye-2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;3.2&quot;,&quot;credit&quot;:&quot;william mercer mcLeod&quot;,&quot;camera&quot;:&quot;NIKON D200&quot;,&quot;caption&quot;:&quot;Rahul Padhye, Rahul Padhye&quot;,&quot;created_timestamp&quot;:&quot;1203418703&quot;,&quot;copyright&quot;:&quot;u00a9 william mercer mcLeod, 415  550-7576&quot;,&quot;focal_length&quot;:&quot;60&quot;,&quot;iso&quot;:&quot;100&quot;,&quot;shutter_speed&quot;:&quot;0.016666666666667&quot;,&quot;title&quot;:&quot;Rahul Padhye, Rahul Padhye&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Rahul Padhye, Rahul Padhye&#8221; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Rahul_Padhye_cipla_BioTech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/rahul-padhye\/\" title=\"Rahul Padhye\">\n\t\t\t\t\t\t\tRahul Padhye\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Vice President and Head, Business Development &amp; Licensing at Cipla Limited<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/rahul-padhye\/\" title=\"Commercializing Biosimilars in Emerging Markets\" target=\"_self\" rel=\"noopener noreferrer\">\n\tCommercializing Biosimilars in Emerging Markets\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Rahul&nbsp;Padhye has been working with Cipla since 2016 as Head BD&amp; Licensing and recently he was assumed responsibility as Global Corporate Development Head.<\/p>\n<p>Prior to this, he worked in Reliance Group for 20+ years in various business divisions such as petroleum marketing, infrastructure, alternative energy and life sciences.<\/p>\n<p>In life sciences business, he was part of the Executive Management team and was responsible for heading global pharmaceuticals and biosimilars business divisions.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/rodeina-challand\/\" title=\"Rodeina Challand\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;32419&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/rodeina-challand\/rodeina_challand_consulting_biotech_pharma_summit_profile_1\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/rodeina_challand_Consulting_BioTech_Pharma_Summit_Profile_1-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/rodeina-challand\/\" title=\"Rodeina Challand\">\n\t\t\t\t\t\t\tRodeina Challand\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Director at Challand Biosimilar Consulting Ltd.<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/rodeina-challand\/\" title=\"Advancing Biosimilars in MENA\/GCC\" target=\"_self\" rel=\"noopener noreferrer\">\n\tAdvancing Biosimilars in MENA\/GCC\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Rodeina Challand B.Sc., Director, Challand Biosimilar Consulting Ltd., Graduate from London University with over 25 years of experience in healthcare, cancer research and pharmaceutical industry across a wide range of roles including developing and implementing clinical development strategies for biosimilars at Hospira Inc. as Director of Clinical Projects and Head of Clinical Operations in the EU.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/roman-ivanov\/\" title=\"Roman Ivanov\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2.jpeg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2-201&#215;300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2-686&#215;1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2-768&#215;1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2-630&#215;940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2-420&#215;627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2-315&#215;470.jpeg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33526&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/roman-ivanov\/roman_ivanov_biocad_biotech_pharma_summit_profile_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2.jpeg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;5&quot;,&quot;credit&quot;:&quot;Kostromin&quot;,&quot;camera&quot;:&quot;Canon EOS 5D Mark III&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;1462964432&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;70&quot;,&quot;iso&quot;:&quot;100&quot;,&quot;shutter_speed&quot;:&quot;0.00625&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2-201&#215;300.jpeg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Roman_Ivanov_Biocad_BioTech_Pharma_Summit_Profile_2-686&#215;1024.jpeg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/roman-ivanov\/\" title=\"Roman Ivanov\">\n\t\t\t\t\t\t\tRoman Ivanov\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Vice President, Research &amp; Development at BIOCAD<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/roman-ivanov\/\" title=\"Clinical studies of mAb biosimilars: are there any regional differences in requirements?\" target=\"_self\" rel=\"noopener noreferrer\">\n\tClinical studies of mAb biosimilars: are there any regional differences in requirements?\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Roman Ivanov is Vice President, International business development, R&amp;D, of biotechnology company BIOCAD, Dean of the Faculty of Molecular and Cell Biotechnology. He is responsible for product development and regulatory affairs.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/steinar-madsen\/\" title=\"Steinar Madsen\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;32399&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2017-speakers\/steinar-madsen\/steinar_madsen_biotech_pharma_summit_norwegian_medicine_agency_profile\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;1.8&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;NIKON D300S&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;1240011838&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;50&quot;,&quot;iso&quot;:&quot;200&quot;,&quot;shutter_speed&quot;:&quot;0.005&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile&#8221; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Steinar_Madsen_BioTech_Pharma_Summit_Norwegian_medicine_agency_profile-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/steinar-madsen\/\" title=\"Steinar Madsen\">\n\t\t\t\t\t\t\tSteinar Madsen\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Medical Director at Norwegian Medicines Agency<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/steinar-madsen\/\" title=\"Biosimlars are accepted \u2013 but is it sustainable?\" target=\"_self\" rel=\"noopener noreferrer\">\n\tBiosimlars are accepted \u2013 but is it sustainable?\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost-effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.<\/p>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/suzette-kox\/\" title=\"Suzette Kox\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"820\" height=\"1224\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2.jpg\" alt=\"\" loading=\"lazy\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221; sizes=&#8221;(max-width: 820px) 100vw, 820px&#8221; data-attachment-id=&#8221;33479&#8243; data-permalink=&#8221;https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/suzette-kox\/suzette_kox_medicines_for_europe_biotech_pharma_summit_2\/&#8221; data-orig-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2.jpg&#8221; data-orig-size=&#8221;820,1224&#8243; data-comments-opened=&#8221;1&#8243; data-image-meta=&#8221;{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;1&quot;}&#8221; data-image-title=&#8221;Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2&#8243; data-image-description=&#8221;&#8221; data-medium-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2-201&#215;300.jpg&#8221; data-large-file=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Suzette_Kox_Medicines_For_Europe_BioTech_Pharma_Summit_2-686&#215;1024.jpg&#8221;>\t\t\t\t\t\t\t<\/a>\n\t\t<h4>\n\t\t\t\t\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/suzette-kox\/\" title=\"Suzette Kox\">\n\t\t\t\t\t\t\tSuzette Kox\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t<h5>Secretary General of IGBA (International Generic and Biosimilar medicines Association)<\/h5>\n<h3>\n\t\t\t<a href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/suzette-kox\/\" title=\"Global Comparator Product for Biosimilar Development and Waiving of Bridging Studies\" target=\"_self\" rel=\"noopener noreferrer\">\n\tGlobal Comparator Product for Biosimilar Development and Waiving of Bridging Studies\n\t\t\t<\/a>\n\t<\/h3>\n\t<p>Suzette Kox was nominated Senior Director International in October 2015, following 14 years in the position of EGA\u2019s Senior Director Scientific Affairs and Coordinator of the European Biosimilars Group (EBG), now Biosimilar Medicines Group, a sector group of Medicines for Europe (formerly EGA). She was the first Chairperson of the Biosimilars Committee of the International Generic and Biosimilar Medicines Association (IGBA).<\/p>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Our Speakers (A-Z) 10years are we closer ?&#8221; target=&#8221;_self&#8221; rel=&#8221;noopener noreferrer&#8221;> Biosimilar global development: after &gt;10years are we closer ? Member of the Austrian Drug Evaluation Committee (sick&nbsp; funds\/reimbursement) Board of Austrian Pharmacological Society (APHAR) Task force Rare Disease Europa Bio and EBE Working Party Advanced Therapies July 2010 -2013: permanent industry representative EUCERD (EU&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31702,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33455","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biosimilars &amp; Biologics 2019 Speakers &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"On 21 &amp; 22 March 2019, Porto will host the 3rd BioTech Pharma Summit: Biosimilars &amp; Biologics 2019. This year\u2019s flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosimilars &amp; Biologics 2019 Speakers &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"On 21 &amp; 22 March 2019, Porto will host the 3rd BioTech Pharma Summit: Biosimilars &amp; Biologics 2019. This year\u2019s flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T11:23:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Biosimilars_Biologics_New_Porto_2019_Gallery_Annual.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"993\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/\",\"name\":\"Biosimilars & Biologics 2019 Speakers &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Biosimilars_Biologics_New_Porto_2019_Gallery_Annual.png\",\"datePublished\":\"2020-08-13T10:04:13+00:00\",\"dateModified\":\"2021-03-18T11:23:51+00:00\",\"description\":\"On 21 & 22 March 2019, Porto will host the 3rd BioTech Pharma Summit: Biosimilars & Biologics 2019. This year\u2019s flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Biosimilars_Biologics_New_Porto_2019_Gallery_Annual.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Biosimilars_Biologics_New_Porto_2019_Gallery_Annual.png\",\"width\":1920,\"height\":993},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars &#038; Biologics 2019 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biosimilars & Biologics 2019 Speakers &#8226; BioTech Pharma Summit","description":"On 21 & 22 March 2019, Porto will host the 3rd BioTech Pharma Summit: Biosimilars & Biologics 2019. This year\u2019s flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Biosimilars & Biologics 2019 Speakers &#8226; BioTech Pharma Summit","og_description":"On 21 & 22 March 2019, Porto will host the 3rd BioTech Pharma Summit: Biosimilars & Biologics 2019. This year\u2019s flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T11:23:51+00:00","og_image":[{"width":1920,"height":993,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Biosimilars_Biologics_New_Porto_2019_Gallery_Annual.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/","name":"Biosimilars & Biologics 2019 Speakers &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Biosimilars_Biologics_New_Porto_2019_Gallery_Annual.png","datePublished":"2020-08-13T10:04:13+00:00","dateModified":"2021-03-18T11:23:51+00:00","description":"On 21 & 22 March 2019, Porto will host the 3rd BioTech Pharma Summit: Biosimilars & Biologics 2019. This year\u2019s flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Biosimilars_Biologics_New_Porto_2019_Gallery_Annual.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Biosimilars_Biologics_New_Porto_2019_Gallery_Annual.png","width":1920,"height":993},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Biosimilars &#038; Biologics 2019 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33455"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33455\/revisions"}],"predecessor-version":[{"id":36000,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33455\/revisions\/36000"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/31702"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}